Faculty
Oncology Division
Alphabetical list (active faculty):   
Brad S. Kahl

Brad S. Kahl, MD

Professor

Department of Medicine

Oncology Division

Medical Oncology

Clinical Interests

  • Lymphoma
  • CLL

Research Interests

  • Clinical trials
  • Novel therapeutics

Contact

  • 314-362-5654 (office)
  • 314-747-5123 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid Campus Center (office)

Original Articles

  • EBV-Positive PCNSL in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes Across a Large Multicenter Cohort
    Agrawal P, David KA, Chen Z, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Gandhi MK, Keane C, Bond DA, Folstad M, Chang J, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon SE, Sieg AG, Cleveland J, Epperla N, Karmali R, Naik S, Smith SM, Rubenstein JL, Kahl BS, Chadburn A, Evens AM, Martin P
    Leuk Lymphoma 2023 May;64(5):1026-1034
  • SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma
    Patel D, Kahl B
    Clin Lymphoma Myeloma Leuk 2023 May 11:S2152-2650(23)00143-X; [ahead of print]
  • Impact of Diagnosis to Treatment Interval in Patients With Newly Diagnosed Mantle Cell Lymphoma
    Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB
    Blood Adv 2023 Jun 13;7(11):2287-2296
  • Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies
    Patel DA, Wan F, Trinkaus K, Guy DG, Edwin N, Watkins M, Bartlett NL, Cashen A, Fehniger TA, Ghobadi A, Mehta-Shah N, Kahl BS
    Clin Lymphoma Myeloma Leuk 2023 Apr 24:S2152-2650(23)00131-3; [ahead of print]
  • Older Patients With Primary Central Nervous System Lymphoma: Survival and Prognostication Across 20 U.S. Cancer Centers
    David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Bond DA, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Folstad M, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, Chang J, Epperla N, Karmali R, Naik S, Martin P, Smith SM, Rubenstein J, Kahl B, Evens AM
    Am J Hematol 2023 Jun;98(6):900-912
  • Is Local Review of Positron Emission Tomography Scans Sufficient in Diffuse Large B-Cell Lymphoma Clinical Trials? A CALGB 50303 Analysis
    Torka P, Pederson LD, Knopp MV, Poon D, Zhang J, Kahl BS, Higley HR, Kelloff G, Friedberg JW, Schwartz LH, Wilson WH, Leonard JP, Bartlett NL, Schoder H, Ruppert AS
    Cancer Med 2023 Apr;12(7):8211-8217
  • Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement and Early Outcomes in Marginal Zone Lymphoma
    Alderuccio JP, Reis IM, Koff JL, Larson MC, Chihara D, Zhao W, Haddadi S, Habermann TM, Martin P, Chapman JR, Strouse C, Kahl BS, Cohen JB, Friedberg JW, Cerhan JR, Flowers CR, Lossos IS
    Blood 2023 Apr 13;141(15):1888-1893
  • A Multicenter Analysis of the Outcomes With Venetoclax in Patients With Relapsed Mantle Cell Lymphoma
    Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaac KM, Portell CA, Mejia Garcia AV, Goldsmith SR, Grover NS, Riedell PA, Karmali R, Burkart M, Buege M, Akhtar OS, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB
    Blood Adv 2023 Feb 21:bloodadvances2022008916; [ahead of print]
  • Checkpoint Inhibitor-Based Salvage Regimens Prior to Autologous Stem Cell Transplant Improve Event-Free Survival in Relapsed/Refractory Classic Hodgkin Lymphoma
    Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Arai S, Chang C, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Murphy J, Ansell S, Jagadish D, Orellana-Noia V, Diefenbach C, Iyenger S, Rappazzo KC, Mishra R, Choi Y, Nowakowski GS, Advani RH, Micallef IN
    Am J Hematol 2023 Mar;98(3):464-471
  • A Multi-Center Analysis of the Impact of DA-EPOCH-R Dose-Adjustment on Clinical Outcomes of Patients With Double/Triple-Hit Lymphoma
    Cortese MJ, Wei W, Cerdena S, Watkins MP, Olson M, Jodon G, Kaiser J, Haverkos B, Hughes ME, Namoglu E, Grover NS, Snow A, Orellana-Noia V, Rainey M, Sohail M, Rudoni J, Portell C, Voorhees T, Landsburg DJ, Kamdar M, Kahl BS, Hill BT
    Leuk Lymphoma 2023 Jan;64(1):107-118
  • Management of Diffuse Large B-Cell Lymphoma: Are We Getting Smarter?
    Kahl BS
    J Clin Oncol 2023 Feb 1;41(4):724-726
  • Clinical Outcomes in Patients Relapsed/Refractory After >/=2 Prior Lines of Therapy for Follicular Lymphoma: A Systematic Literature Review and Meta-Analysis
    Kanters S, Ball G, Kahl B, Wiesinger A, Limbrick-Oldfield EH, Sudhindra A, Snider JT, Patel AR
    BMC Cancer 2023 Jan 23;23(1):74
  • Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
    Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, Switchenko JM, Kahl B, Maddocks K, Grover NS, Qi K, Parisi L, Daly K, Zhu A, Salles G
    J Clin Oncol 2023 Jan 20;41(3):541-554
  • Outcomes of Patients With Limited-Stage Plasmablastic Lymphoma: A Multi-Institutional Retrospective Study
    Hess BT, Giri A, Park Y, Patel KK, Link BK, Nowakowski GS, Maliske SM, Fortin S, Chavez JC, Saeed H, Hill BT, Mejia Garcia AV, Maddocks KJ, Hanel W, Wagner-Johnston ND, Messmer MR, Kahl BS, Watkins M, Alderuccio JP, Lossos IS, Nathan S, Orellana-Noia VM, Portell CA, Landsburg DJ, Ayers EC, Castillo JJ
    Am J Hematol 2023 Feb;98(2):300-308
  • Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials
    Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger JM, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar SJ, Leonard JP
    J Clin Oncol 2023 Jan 10;41(2):336-342
  • Top Advances in Lymphoma for 2021
    Patel DA, Kahl BS
    Cancer 2022 Dec 1;128(23):4047-4051
  • Extranodal Presentation in Limited-Stage Diffuse Large Bcell Lymphoma as a Prognostic Marker in Three SWOG Trials S0014, S0313 and S1001
    Stephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Song JY, LeBlanc ML, Smith SM, Persky DO, Friedberg JW
    Haematologica 2022 Nov 1;107(11):2732-2736
  • Upfront Therapy for Diffuse Large B-Cell Lymphoma: Looking Beyond R-CHOP
    Hill BT, Kahl B
    Expert Rev Hematol 2022 Sep;15(9):805-812
  • The International Consensus Classification of Mature Lymphoid Neoplasms: A Report From the Clinical Advisory Committee
    Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d'Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD
    Blood 2022 Sep 15;140(11):1229-1253
  • Zanubrutinib Versus Bendamustine and Rituximab in Untreated Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma (SEQUOIA): A Randomised, Controlled, Phase 3 Trial
    Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Simkovic M, Shadman M, Osterborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trneny M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P
    Lancet Oncol 2022 Aug;23(8):1031-1043
  • Evaluating the Impact of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Cohort Analysis
    Luan D, Fatola T, Toure A, Flowers CR, Link B, Friedberg JW, Cohen JB, Kahl B, Lossos IS, Nastoupil L, Maurer MJ, Cerhan JR, Martin P
    Blood Adv 2022 Aug 9;6(15):4413-4423
  • Loncastuximab Tesirine in Relapsed/Refractory High-Grade B-Cell Lymphoma: A Subgroup Analysis From the LOTIS-2 Study
    Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF
    Blood Adv 2022 Aug 23;6(16):4736-4739
  • Metabolic Biomarkers Assessed With PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients With Diffuse Large B-Cell Lymphoma
    Jaswal S, Sanders V, Pullarkat P, Teja S, Salter A, Watkins MP, Atagu N, Ludwig DR, Mhlanga J, Mellnick VM, Peterson LR, Bartlett NL, Kahl BS, Fehniger TA, Ghobadi A, Cashen AF, Mehta-Shah N, Ippolito JE
    Cancers (Basel) 2022 Jun 14;14(12):2932
  • Long-Term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-Up
    Dreyling M, Goy A, Hess G, Kahl BS, Hernandez-Rivas JA, Schuier N, Qi K, Deshpande S, Zhu A, Parisi L, Wang ML
    Hemasphere 2022 Apr 13;6(5):e712
  • Treatment Patterns and Outcomes of Patients With Relapsed or Refractory Follicular Lymphoma Receiving Three or More Lines of Systemic Therapy (LEO CReWE): A Multicentre Cohort Study
    Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK, Maurer MJ
    Lancet Haematol 2022 Apr;9(4):e289-e300
  • COVID-19 Booster Vaccines Generate Seroconversion in Subset of Patients With Lymphoma/CLL: Single Institution Experience
    Mehta-Shah N, Bartlett NL, Kahl B, Watkins MP, Dubois A, Schmelzle G, Waqar S, Ballman C, Wan F, Farnsworth CW
    Leuk Lymphoma 2022 Jul;63(7):1723-1727
  • An International Analysis Evaluating Frontline Bendamustine With Rituximab in Extranodal Marginal Zone Lymphoma
    Alderuccio JP, Arcaini L, Watkins MP, Beaven AW, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert AB, Olszewski AJ, Kim SH, Hess B, Gaballa S, Ayyappan S, Castillo JJ, Argnani L, Voorhees TJ, Saba R, Chowdhury SM, Vargas F, Reis IM, Kwon D, Alexander JS, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link BK, Logothetis CN, Herrera AF, Friedberg JW, Kahl BS, Luminari S, Zinzani PL, Lossos IS
    Blood Adv 2022 Apr 12;6(7):2035-2044
  • Improving Eligibility Criteria for First-Line Trials for Patients With DLBCL Using a US-Based Delphi-Method Survey
    Harkins RA, Patel SP, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum KA, Cashen AF, Casulo C, Friedberg JW, Johnston PB, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan PM, Westin JR, Koff JL, Flowers CR
    Blood Adv 2022 May 10;6(9):2745-2756
  • The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy
    Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, Solh M, Kahl BS, Hamadani M
    Clin Lymphoma Myeloma Leuk 2022 May;22(5):e335-e339
  • Dose-Finding Study of Ibrutinib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma
    Portell CA, Wages NA, Kahl BS, Budde LE, Chen RW, Cohen JB, Varhegyi NE, Petroni GR, Williams ME
    Blood Adv 2022 Mar 8;6(5):1490-1498
  • Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Spira A, Zhou X, Chen L, Gnanasakthy A, Wang L, Ungar D, Curiel R, Liao L, Radford J, Kahl B
    Clin Lymphoma Myeloma Leuk 2022 Mar;22(3):158-168
  • Single-Route CNS Prophylaxis for Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes From 21 US Academic Institutions
    Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA
    Blood 2022 Jan 20;139(3):413-423
  • Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma: A Cohort of a Multicentre, Single-Arm, Phase 1b/2 Study
    Diefenbach C, Kahl BS, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke JM, Hirata J, Jiang Y, Paulson JN, Chang YM, Musick L, Abrisqueta P
    Lancet Haematol 2021 Dec;8(12):e891-e901
  • Early Relapse Identifies MCL Patients With Inferior Survival After Intensive or Less Intensive Frontline Therapy
    Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen JB
    Blood Adv 2021 Dec 14;5(23):5179-5189
  • American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
    Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS
    Transplant Cell Ther 2021 Sep;27(9):720-728
  • ASTCT, CIBMTR, and EBMT Clinical Practice Recommendations for Transplant and Cellular Therapies in Mantle Cell Lymphoma
    Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS
    Bone Marrow Transplant 2021 Dec;56(12):2911-2921
  • Multi-Center Analysis of Practice Patterns and Outcomes of Younger and Older Patients With Mantle Cell Lymphoma in the Rituximab Era
    Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB
    Am J Hematol 2021 Nov 1;96(11):1374-1384
  • Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 ((111)In)/Yttrium 90 ((90)Y) Ibritumomab Tiuxetan (Zevalin((R))) Theranostic Pair in Patients With Lymphoma at Myeloablative Dose Levels
    Wahl RL, Frey EC, Jacene HA, Kahl BS, Piantadosi S, Bianco JA, Hammes RJ, Jung M, Kasecamp W, He B, Sgouros G, Flinn IW, Swinnen LJ
    Cancers (Basel) 2021 Jun 6;13(11)
  • Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial
    Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C
    Lancet Oncol 2021 Jun;22(6):790-800
  • Intensive Induction Regimens After Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated With Improved Survival
    Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB
    Eur J Haematol 2021 Sep;107(3):301-310
  • Phase I Trial of N-803, an IL15 Receptor Agonist, With Rituximab in Patients With Indolent Non-Hodgkin Lymphoma
    Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA
    Clin Cancer Res 2021 Jun 15;27(12):3339-3350
  • Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
    Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM, Wagner-Johnston N, Casulo C, Wade JL, Nagargoje GG, Reynolds CM, Cohen JB, Khan N, Amengual JE, Richards KL, Little RF, Leonard JP, Friedberg JW, Kostakoglu L, Kahl BS, Witzig TE
    J Clin Oncol 2021 Apr 20;39(12):1329-1338
  • Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
    Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, Ardeshna KM, Townsend W, Solh M, Heffner LT, Ungar D, Wang L, Boni J, Havenith K, Qin Y, Kahl BS
    Blood 2021 May 13;137(19):2634-2645
  • Zanubrutinib Monotherapy for Patients With Treatment Naive Chronic Lymphocytic Leukemia and 17p Deletion
    Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, Simpson D, Shadman M, Ganly PS, Laurenti L, Opat S, Tani M, Ciepluch H, Verner E, Simkovic M, Osterborg A, Trneny M, Tedeschi A, Paik JC, Kuwahara SB, Feng S, Ramakrishnan V, Cohen A, Huang J, Hillmen P, Brown JR
    Haematologica 2020 Oct 13;Online ahead of print
  • Ipilimumab, Nivolumab, and Brentuximab Vedotin Combination Therapies in Patients With Relapsed or Refractory Hodgkin Lymphoma: Phase 1 Results of an Open-Label, Multicentre, Phase 1/2 Trial
    Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM
    Lancet Haematol 2020 Sep;7(9):e660-e670
  • CD19 Antibody-Drug Conjugate Therapy in DLBCL Does Not Preclude Subsequent Responses to CD19-Directed CAR T-Cell Therapy
    Thapa B, Caimi PF, Ardeshna KM, Solh M, Carlo-Stella C, Kahl BS, Hamadani M
    Blood Adv 2020 Aug 25;4(16):3850-3852
  • Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
    Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD 3rd, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW
    J Clin Oncol 2020 Sep 10;38(26):3003-3011
  • CAR-Modified Memory-Like NK Cells Exhibit Potent Responses to NK-Resistant Lymphomas
    Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila M, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, Kahl BS, Kim MY, Cooper ML, DiPersio JF, Berrien-Elliott MM, Fehniger TA
    Blood 2020 Nov 12;136(20):2308-2318
  • Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results From the CALGB 50303 Clinical Trial
    Schoder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz AD, Cheson BD, Wagner-Johnston N, Kahl BS, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL
    Blood 2020 Jun 18;135(25):2224-2234
  • Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Analysis of SWOG S0816
    Ha CS, LeBlanc M, Schoder H, Pinnix CC, Bartlett NL, Evens AM, Hsi ED, Rimsza L, Knopp MV, Zhang J, Leonard JP, Kahl BS, Li H, Smith S, Constine LS, Friedberg JW
    Leuk Lymphoma 2020 Oct;61(10):2442-2447
  • A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab With Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
    Evens AM, Hong F, Habermann TM, Advani RH, Gascoyne RD, Witzig TE, Quon A, Ranheim EA, Ansell SM, Cheema PS, Dy PA, O'Brien TE, Winter JN, Cescon TP, Chang JE, Kahl BS
    Clin Cancer Res 2020 Sep 1;26(17):4468-4477
  • Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
    Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH
    J Clin Oncol 2020 Aug 1;38(22):2519-2529
  • Rituximab/Bendamustine and Rituximab/Cytarabine Induction Therapy for Transplant-Eligible Mantle Cell Lymphoma
    Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E
    Blood Adv 2020 Mar 10;4(5):858-867
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology
    Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H
    J Natl Compr Canc Netw 2020 Feb;18(2):185-217
  • Outcomes in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma After Intensive Frontline Treatment Failure
    Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ
    Cancer 2020 Jan 15;126(2):293-303
  • Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients After Front-Line Therapy From the COMPLETE Registry
    Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM
    Acta Haematol 2020;143(1):40-50
  • MRD Response in Relapsed/Refractory FL After Obinutuzumab Plus Bendamustine or Bendamustine Alone in the GADOLIN Trial
    Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, Kehden B, Nicolas-Virelizier E, Spielewoy N, Fingerle-Rowson G, Harbron C, Mundt K, Wassner-Fritsch E, Cheson BD
    Leukemia 2020 Feb;34(2):522-532
  • Five-Year Outcomes of the S1106 Study of R-Hyper-CVAD Vs R-Bendamustine in Transplant-Eligible Patients With Mantle Cell Lymphoma
    Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM
    Blood Adv 2019 Oct 22;3(20):3132-3135
  • A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
    Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, Feingold JM, Ardeshna KM, Solh M, Heffner LT, Ungar D, He S, Boni J, Havenith K, O'Connor OA
    Clin Cancer Res 2019 Dec 1;25(23):6986-6994
  • Five-Year Follow-Up of SWOG S0816: Limitations and Values of a PET-Adapted Approach With Stage III/IV Hodgkin Lymphoma
    Stephens DM, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW
    Blood 2019 Oct 10;134(15):1238-1246
  • Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
    Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schoder H, Zelenetz AD, Leonard JP
    J Clin Oncol 2019 Jul 20;37(21):1790-1799
  • Follicular Lymphoma Patients With KIR2DL2 and KIR3DL1 and Their Ligands (HLA-C1 and HLA-Bw4) Show Improved Outcome When Receiving Rituximab
    Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, Mendonca EA, Song Y, Kenkre VP, Hong F, Gascoyne RD, Paietta E, Horning SJ, Miller JS, Kahl B, Sondel PM
    J Immunother Cancer 2019 Mar 12;7(1):70
  • First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
    Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM
    J Clin Oncol 2019 Apr 20;37(12):984-991
  • Serum Levels of TARC, MDC, IL-10, and Soluble CD163 in Hodgkin Lymphoma: A SWOG S0816 Correlative Study
    Hsi ED, Li H, Nixon AB, Schoder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW
    Blood 2019 Apr 18;133(16):1762-1765
  • Recent Advances and Future Directions in Mantle Cell Lymphoma Research: Report of the 2018 Mantle Cell Lymphoma Consortium Workshop
    Kahl BS, Dreyling M, Gordon LI, Martin P, Quintanilla-Martinez L, Sotomayor EM
    Leuk Lymphoma 2019 Aug;60(8):1853-1865
  • The Role of Autologous Stem Cell Transplantation in Patients With Nodal Peripheral T-Cell Lymphomas in First Complete Remission: Report From COMPLETE, a Prospective, Multicenter Cohort Study
    Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR
    COMPLETE Investigators
    Cancer 2019 May 1;125(9):1507-1517
  • NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
    Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H
    J Natl Compr Canc Netw 2019 Jan;17(1):12-20
  • Autologous Transplantation as Consolidation for High Risk Aggressive T-Cell Non-Hodgkin Lymphoma: A SWOG 9704 Intergroup Trial Subgroup Analysis
    Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ
    Leuk Lymphoma 2019 Aug;60(8):1934-1941
  • Maintenance Rituximab or Observation After Frontline Treatment With Bendamustine-Rituximab for Follicular Lymphoma
    Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS
    Br J Haematol 2019 Feb;184(4):524-535
  • Dose-Adjusted EPOCH-R (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab) in Untreated Aggressive Diffuse Large B-Cell Lymphoma With MYC Rearrangement: A Prospective, Multicentre, Single-Arm Phase 2 Study
    Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH
    Lancet Haematol 2018 Dec;5(12):e609-e617
  • Ibrutinib for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Extended 3.5-Year Follow Up From a Pooled Analysis
    Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl BS, Hernandez-Rivas JA, Qi K, Deshpande S, Parisi L, Wang M
    Haematologica 2019 May;104(5):e211-e214
  • Duvelisib, an Oral Dual PI3K-Delta,Gamma Inhibitor, Shows Clinical and Pharmacodynamic Activity in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in a Phase 1 Study
    O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I
    Am J Hematol 2018 Nov;93(11):1318-1326
  • Duvelisib, an Oral Dual PI3K-Delta, Gamma Inhibitor, Shows Clinical Activity in Indolent Non-Hodgkin Lymphoma in a Phase 1 Study
    Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B
    Am J Hematol 2018 Nov;93(11):1311-1317
  • CALGB 50604: Risk-Adapted Treatment of Nonbulky Early-Stage Hodgkin Lymphoma Based on Interim PET
    Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schoder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL
    Blood 2018 Sep 6;132(10):1013-1021
  • High-Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements With Diffuse Large B-Cell Lymphoma Morphology
    Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A
    Blood 2018 May 3;131(18):2060-2064
  • Rapid, Real Time Pathology Review for ECOG/ACRIN 1412: A Novel and Successful Paradigm for Future Lymphoma Clinical Trials in the Precision Medicine Era
    King RL, Nowakowski GS, Witzig TE, Scott DW, Little RF, Hong F, Gascoyne RD, Kahl BS, Macon WR
    Blood Cancer J 2018 Feb 28;8(3):27
  • Outcomes in Adolescents and Young Adults With Hodgkin Lymphoma Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis
    Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM
    Cancer 2018 Jan 1;124(1):136-144
  • VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study
    Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS
    Clin Lymphoma Myeloma Leuk 2018 Jan;18(1):e61-e67
  • Duvelisib, a Novel Oral Dual Inhibitor of PI3K-Delta,Gamma, Is Clinically Active in Advanced Hematologic Malignancies
    Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S
    Blood 2018 Feb 22;131(8):877-887
  • NR4A1 Inhibition Synergizes With Ibrutinib in Killing Mantle Cell Lymphoma Cells
    Li Y, Wang F, Lu L, Zhu F, Huang S, Nomie K, Zhang L, Yang DT, Huang W, Kahl BS, Safe S, Wang M, Rui L
    Blood Cancer J 2017 Nov 23;7(12):632
  • Outcomes in 370 Patients With Mantle Cell Lymphoma Treated With Ibrutinib: A Pooled Analysis From Three Open-Label Studies
    Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Cavazos N, Liu B, Yang S, Clow F, Goldberg JD, Beaupre D, Vermeulen J, Wildgust M, Wang M
    Br J Haematol 2017 Nov;179(3):430-438
  • Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
    Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H
    J Natl Compr Canc Netw 2017 Nov;15(11):1414-1427
  • HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome as Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
    Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM
    Front Immunol 2017 Jun 12;8:675
  • Long-Term Safety Experience With Bendamustine for Injection in a Real-World Setting
    Martin P, Barr PM, James L, Pathak A, Kahl B
    Expert Opin Drug Saf 2017 Jun;16(6):647-650
  • Idelalisib Is Effective in Patients With High-Risk Follicular Lymphoma and Early Relapse After Initial Chemoimmunotherapy
    Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA, Friedberg JW
    Blood 2017 Jun 1;129(22):3037-3039
  • Recent Advances and Future Directions in Mantle Cell Lymphoma Research: Report of the 2016 Mantle Cell Lymphoma Consortium Workshop
    Kahl BS, Dreyling M, Gordon LI, Quintanilla-Martinez L, Sotomayor EM
    Leuk Lymphoma 2017 Jul;58(7):1561-1569
  • Efficacy and Safety of Idelalisib in Patients With Relapsed, Rituximab- And Alkylating Agent-Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase 2 Study
    Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Martin P, Kim Y, Shreay S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK
    Haematologica 2017 Apr;102(4):e156-e159
  • Analysis of Peripheral T-Cell Lymphoma Diagnostic Workup in the United States
    Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM
    Clin Lymphoma Myeloma Leuk 2017 Apr;17(4):193-200
  • Phase I First-In-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
    Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF
    J Clin Oncol 2017 Mar 10;35(8):826-833
  • RB but Not R-HCVAD Is a Feasible Induction Regimen Prior to Auto-HCT in Frontline MCL: Results of SWOG Study S1106
    Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW
    Br J Haematol 2017 Mar;176(5):759-769
  • A Prospective Cohort Study of Patients With Peripheral T-Cell Lymphoma in the United States
    Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM
    Cancer 2017 Apr 1;123(7):1174-1183
  • Investigator and Independent Review Committee Exploratory Assessment and Verification of Tumor Response in a Non-Hodgkin Lymphoma Study
    Ford RR, Ford RW, O'Neal M, Kahl BS, Chen L, Munteanu M, Cheson BD
    Leuk Lymphoma 2017 Jun;58(6):1332-1340
  • Mantle Cell Lymphoma Initial Therapy With Abbreviated R-CHOP Followed by 90Y-Ibritumomab Tiuxetan: 10-Year Follow-Up of the Phase 2 ECOG-ACRIN Study E1499
    Smith MR, Hong F, Li H, Gordon LI, Gascoyne RD, Paietta EM, Advani RH, Forero-Torres A, Horning SJ, Kahl BS
    Leukemia 2017 Feb;31(2):517-519
  • Recommendations for Clinical Trial Development in Follicular Lymphoma
    Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM
    J Natl Cancer Inst 2016 Dec 31;109(3):djw255
  • General Biomarker Recommendations for Lymphoma
    Rimsza L, Fedoriw Y, Staudt LM, Melnick A, Gascoyne R, Crump M, Baizer L, Fu K, Hsi E, Chan JW, McShane L, Leonard JP, Kahl BS, Little RF, Friedberg JW, Kostakoglu L
    J Natl Cancer Inst 2016 Dec 16;108(12)
  • Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
    Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH, Leonard JP, Smith SM
    J Natl Cancer Inst 2016 Dec 16;108(12)
  • The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Hematologic Malignancies: Multiple Myeloma, Lymphoma, and Acute Leukemia
    Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV
    J Immunother Cancer 2016 Dec 20;4:90
  • T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment
    Casulo C, O'Connor O, Shustov A, Fanale M, Friedberg JW, Leonard JP, Kahl BS, Little RF, Pinter-Brown L, Advani R, Horwitz S
    J Natl Cancer Inst 2016 Dec 31;109(2):djw248
  • Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations
    Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF, Baizer L, Evens AM, Hoppe RT, Kelly KM, Persky DO, Younes A, Kostakaglu L, Bartlett NL
    J Natl Cancer Inst 2016 Dec 31;109(4):djw249
  • Recommendations for Clinical Trial Development in Mantle Cell Lymphoma
    Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR
    J Natl Cancer Inst 2016 Dec 31;109(1):djw263
  • Longitudinal Body Composition Changes in Diffuse Large B-Cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans
    Xiao DY, Luo S, O'Brian K, Sanfilippo KM, Ganti A, Riedell P, Lynch RC, Liu W, Kahl BS, Cashen AF, Fehniger TA, Carson KR
    J Natl Cancer Inst 2016 Jul 5;108(11):djw145
  • Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
    Crump M, Leppa S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SP, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T
    J Clin Oncol 2016 Jul 20;34(21):2484-92
  • Randomized Phase 3 Study in Low-Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody With Observation After Induction Therapy: A Trial of the ECOG-ACRIN Cancer Research Group (E1496)
    Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS
    Cancer 2016 Oct;122(19):2996-3004
  • US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
    Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW
    J Clin Oncol 2016 Jun 10;34(17):2020-7
  • FBXO10 Deficiency and BTK Activation Upregulate BCL2 Expression in Mantle Cell Lymphoma
    Li Y, Bouchlaka MN, Wolff J, Grindle KM, Lu L, Qian S, Zhong X, Pflum N, Jobin P, Kahl BS, Eickhoff JC, Wuerzberger-Davis SM, Miyamoto S, Thomas CJ, Yang DT, Capitini CM, Rui L
    Oncogene 2016 Dec 1;35(48):6223-6234
  • Rituximab Extended Schedule or Retreatment Trial for Low Tumour Burden Non-Follicular Indolent B-Cell Non-Hodgkin Lymphomas: Eastern Cooperative Oncology Group Protocol E4402
    Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS
    Br J Haematol 2016 Jun;173(6):867-75
  • Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients With Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients
    Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C
    Biol Blood Marrow Transplant 2016 Sep;22(9):1543-51
  • Bendamustine + Rituximab Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed, Refractory Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma: A Wisconsin Oncology Network Study
    Chang JE, Havighurst T, Kim K, Eickhoff J, Traynor AM, Kirby-Slimp R, Volk LM, Werndli J, Go RS, Weiss M, Blank J, Kahl BS
    Br J Haematol 2016 Apr;173(2):283-91
  • Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
    Burke JM, van der Jagt RH, Kahl BS, Wood P, Hawkins TE, MacDonald D, Hertzberg M, Simpson D, Craig M, Kolibaba K, Issa S, Munteanu M, Victor TW, Flinn IW
    Clin Lymphoma Myeloma Leuk 2016 Apr;16(4):182-190e1
  • Outcomes of MYC-Associated Lymphomas After R-CHOP With and Without Consolidative Autologous Stem Cell Transplant: Subset Analysis of Randomized Trial Intergroup SWOG S9704
    Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM
    Br J Haematol 2016 Sep;174(5):686-91
  • Optimal Use of Bendamustine in Hematologic Disorders: Treatment Recommendations From an International Consensus Panel - An Update
    Cheson BD, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, Ogura M, Weidmann E, Wendtner CM, Zinzani PL
    Leuk Lymphoma 2016 Apr;57(4):766-782
  • Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma
    Kenkre VP, Hong F, Cerhan JR, Lewis M, Sullivan L, Williams ME, Gascoyne RD, Horning SJ, Kahl BS
    Clin Cancer Res 2016 Feb 15;22(4):821-6
  • Personalized Risk Prediction for Event-Free Survival at 24 Months in Patients With Diffuse Large B-Cell Lymphoma
    Maurer MJ, Jais JP, Ghesquieres H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O, Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, Salles G, Habermann TM, Tilly H, Cerhan JR
    Am J Hematol 2016 Feb;91(2):179-184
  • Targeting BCL2 With Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF
    N Engl J Med 2016 Jan 28;374(4):311-322
  • Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for Advanced Hodgkin Lymphoma in the Modern Era
    Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH
    Br J Haematol 2015 Nov;171(4):530-8
  • A Phase 2 Study of Weekly Temsirolimus and Bortezomib for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Wisconsin Oncology Network Study
    Fenske TS, Shah NM, Kim KM, Saha S, Zhang C, Baim AE, Farnen JP, Onitilo AA, Blank JH, Ahuja H, Wassenaar T, Qamar R, Mansky P, Traynor AM, Mattison RJ, Kahl BS
    Cancer 2015 Oct 1;121(19):3465-71
  • Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108
    Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW
    J Clin Oncol 2015 Jul 20;33(21):2399-404
  • Long-Term Follow-Up of MCL Patients Treated With Single-Agent Ibrutinib: Updated Safety and Efficacy Results
    Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S
    Blood 2015 Aug 6;126(6):739-45
  • A Phase II Trial of RCHOP Followed by Radioimmunotherapy for Early Stage (Stages I/II) Diffuse Large B-Cell Non-Hodgkin Lymphoma: ECOG3402
    Witzig TE, Hong F, Micallef IN, Gascoyne RD, Dogan A, Wagner H Jr, Kahl BS, Advani RH, Horning SJ
    Br J Haematol 2015 Sep;170(5):679-86
  • Phase 1 Study of the Safety, Pharmacokinetics, and Antitumour Activity of the BCL2 Inhibitor Navitoclax in Combination With Rituximab in Patients With Relapsed or Refractory CD20(+) Lymphoid Malignancies
    Roberts AW, Advani RH, Kahl BS, Persky D, Sweetenham JW, Carney DA, Yang J, Busman TB, Enschede SH, Humerickhouse RA, Seymour JF
    Br J Haematol 2015 Sep;170(5):669-78
  • Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial
    Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ
    J Clin Oncol 2015 Jun 10;33(17):1936-42
  • Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [18F] FDG-PET Scanning: ECOG-ACRIN Cancer Research Group Study (E3404)
    Swinnen LJ, Li H, Quon A, Gascoyne R, Hong F, Ranheim EA, Habermann TM, Kahl BS, Horning SJ, Advani RH
    Br J Haematol 2015 Jul;170(1):56-65
  • High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Reveals Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma
    Kuo PY, Leshchenko VV, Fazzari MJ, Perumal D, Gellen T, He T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh KS, Goy A, Yang DT, Chan WC, Kahl BS, Verma AK, Gascoyne RD, Kimby E, Sander B, Ye BH, Melnick AM, Parekh S
    Oncogene 2015 Mar 5;34(10):1231-40
  • Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT)
    Wagner LI, Zhao F, Hong F, Williams ME, Gascoyne RD, Krauss JC, Advani RH, Go RS, Habermann TM, Leach JW, O'Connor B, Schuster SJ, Cella D, Horning SJ, Kahl BS
    J Clin Oncol 2015 Mar 1;33(7):740-8
  • Rituximab Extended Schedule or Re-Treatment Trial for Low-Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402
    Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ
    J Clin Oncol 2014 Oct 1;32(28):3096-102
  • Yttrium 90-Ibritumomab Tiuxetan Plus Rituximab Maintenance as Initial Therapy for Patients With High-Tumor-Burden Follicular Lymphoma: A Wisconsin Oncology Network Study
    Rajguru S, Kristinsdottir T, Eickhoff J, Peterson C, Meyer CM, Traynor AM, Kahl BS
    Clin Adv Hematol Oncol 2014 Aug;12(8):509-15
  • A Phase 1 Study of the PI3Kdelta Inhibitor Idelalisib in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
    Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND
    Blood 2014 May 29;123(22):3398-405
  • Idelalisib, an Inhibitor of Phosphatidylinositol 3-Kinase p110delta, for Relapsed/Refractory Chronic Lymphocytic Leukemia
    Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR
    Blood 2014 May 29;123(22):3390-7
  • Idelalisib, a Selective Inhibitor of Phosphatidylinositol 3-Kinase-Delta, as Therapy for Previously Treated Indolent Non-Hodgkin Lymphoma
    Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE
    Blood 2014 May 29;123(22):3406-13
  • Randomized Trial of Bendamustine-Rituximab or R-CHOP/R-CVP in First-Line Treatment of Indolent NHL or MCL: The BRIGHT Study
    Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM
    Blood 2014 May 8;123(19):2944-52
  • Bevacizumab and Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone in Combination for Patients With Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Oncology Group Study (E2404)
    Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ, Habermann TM, Kahl BS, Advani RH
    Leuk Lymphoma 2014 Apr;55(4):768-72
  • The Role of Body Mass Index in Survival Outcome for Lymphoma Patients: US Intergroup Experience
    Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahl BS
    Ann Oncol 2014 Mar;25(3):669-74
  • Phase 2 Study of VcR-CVAD With Maintenance Rituximab for Untreated Mantle Cell Lymphoma: An Eastern Cooperative Oncology Group Study (E1405)
    Chang JE, Li H, Smith MR, Gascoyne RD, Paietta EM, Yang DT, Advani RH, Horning SJ, Kahl BS
    Blood 2014 Mar 13;123(11):1665-73
  • PI3Kdelta Inhibition by Idelalisib in Patients With Relapsed Indolent Lymphoma
    Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA
    N Engl J Med 2014 Mar 13;370(11):1008-18
  • Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
    Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI
    N Engl J Med 2013 Oct 31;369(18):1681-90
  • Targeting BTK With Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
    Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA
    N Engl J Med 2013 Aug 8;369(6):507-16
  • A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Diffuse Large B Cell Lymphoma: An Eastern Cooperative Oncology Group Study (E1404)
    Greenwald DR, Li H, Luger SM, Go RS, King D, Patel T, Gascoyne RD, Kolesar J, Kahl BS, Horning S
    J Hematol Oncol 2013 Jul 5;6:46
  • Immunohistochemical Evaluation of MYC Expression in Mantle Cell Lymphoma
    Oberley MJ, Rajguru SA, Zhang C, Kim K, Shaw GR, Grindle KM, Kahl BS, Kanugh C, Laffin J, Yang DT
    Histopathology 2013 Oct;63(4):499-508
  • Patients With Diffuse Large B-Cell Lymphoma of Germinal Center Origin With BCL2 Translocations Have Poor Outcome, Irrespective of MYC Status: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study
    Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W, O'Neill S, Ponzoni M, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Moller MB, Wu L, Medeiros LJ, Young KH
    Haematologica 2013 Feb;98(2):255-63
  • Plasma Epstein-Barr Virus DNA Predicts Outcome in Advanced Hodgkin Lymphoma: Correlative Analysis From a Large North American Cooperative Group Trial
    Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl BS, Horning SJ, Ambinder RF
    Blood 2013 May 2;121(18):3547-53
  • The Efficacy and Tolerability of Adriamycin, Bleomycin, Vinblastine, Dacarbazine and Stanford V in Older Hodgkin Lymphoma Patients: A Comprehensive Analysis From the North American Intergroup Trial E2496
    Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ
    Br J Haematol 2013 Apr;161(1):76-86
  • Incremental Value in Outcome Prediction With Gene Expression-Based Signatures in Diffuse Large B-Cell Lymphoma
    Hong F, Kahl BS, Gray R
    Blood 2013 Jan 3;121(1):156-8
  • Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma
    Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD
    J Clin Oncol 2013 Feb 20;31(6):692-700
  • Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
    Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ
    J Clin Oncol 2013 Feb 20;31(6):684-91
  • Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP: Report From an International DLBCL Rituximab-CHOP Consortium Program Study
    Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Kahl BS, Winter JN, Xu W, Li J, Go RS, Li Y, Piris MA, Moller MB, Miranda RN, Abruzzo LV, Medeiros LJ, Young KH
    Blood 2012 Nov 8;120(19):3986-96
  • Comprehensive Gene Expression Profiling and Immunohistochemical Studies Support Application of Immunophenotypic Algorithm for Molecular Subtype Classification in Diffuse Large B-Cell Lymphoma: A Report From the International DLBCL Rituximab-CHOP Consortium Program Study
    Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d'Amore ES, Montes-Moreno S, Dybkaer K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O'Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Moller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH
    Leukemia 2012 Sep;26(9):2103-13
  • Tumor-Associated Macrophages Predict Inferior Outcomes in Classic Hodgkin Lymphoma: A Correlative Study From the E2496 Intergroup Trial
    Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD
    Blood 2012 Oct 18;120(16):3280-7
  • Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499
    Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, Kahl BS, Advani R, Hong F, Horning SJ
    J Clin Oncol 2012 Sep 1;30(25):3119-26
  • Microscale Functional Cytomics for Studying Hematologic Cancers
    Young EW, Pak C, Kahl BS, Yang DT, Callander NS, Miyamoto S, Beebe DJ
    Blood 2012 Mar 8;119(10):e76-85
  • Cardiac Toxicity Associated With Bevacizumab (Avastin) in Combination With CHOP Chemotherapy for Peripheral T Cell Lymphoma in ECOG 2404 Trial
    Advani RH, Hong F, Horning SJ, Kahl BS, Manola J, Swinnen LJ, Habermann TM, Ganjoo K
    Leuk Lymphoma 2012 Apr;53(4):718-20
  • Maintenance Rituximab Following Induction Chemo-Immunotherapy for Mantle Cell Lymphoma: Long-Term Follow-Up of a Pilot Study From the Wisconsin Oncology Network
    Kenkre VP, Long WL, Eickhoff JC, Blank JH, McFarland TA, Bottner W, Rezazedeh H, Werndli JE, Bailey HH, Kahl BS
    Leuk Lymphoma 2011 Sep;52(9):1675-80
  • VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study
    Chang JE, Peterson C, Choi S, Eickhoff JC, Kim K, Yang DT, Gilbert LA, Rogers ES, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS
    Br J Haematol 2011 Oct;155(2):190-7
  • Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study
    Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD
    J Clin Oncol 2011 Sep 1;29(25):3389-95
  • Long-Term Follow-Up of Symptomatic Patients With Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia Treated With the Anti-CD52 Monoclonal Antibody Alemtuzumab
    Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M
    Blood 2011 Jul 14;118(2):276-81
  • Treatment of Synchronous Mantle Cell Lymphoma and Small Lymphocytic Lymphoma With Bendamustine and Rituximab
    Kourelis TV, Kahl BS, Benn P, Delach JA, Bilgrami SF
    Acta Haematol 2011;126(1):40-3
  • Evaluation of Sulfonamide Detoxification Pathways in Haematologic Malignancy Patients Prior to Intermittent Trimethoprim-Sulfamethoxazole Prophylaxis
    Abouraya M, Sacco JC, Kahl BS, Trepanier LA
    Br J Clin Pharmacol 2011 Apr;71(4):566-74
  • Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
    Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L
    Clin Lymphoma Myeloma Leuk 2010 Dec;10(6):452-7
  • Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study
    Chang JE, Seo S, Kim KM, Werndli JE, Bottner WA, Rodrigues GA, Sanchez FA, Saphner TJ, Longo WL, Kahl BS
    Clin Lymphoma Myeloma Leuk 2010 Oct;10(5):379-84
  • Genomewide DNA Methylation Analysis Reveals Novel Targets for Drug Development in Mantle Cell Lymphoma
    Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, Muthusamy N, Kahl BS, Byrd JC, Wiestner A, Melnick A, Parekh S
    Blood 2010 Aug 19;116(7):1025-34
  • Autologous Versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients With Chemosensitive Follicular Non-Hodgkin Lymphoma Beyond First Complete Response or First Partial Response
    Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG
    Biol Blood Marrow Transplant 2011 Jul;17(7):1051-7
  • Use of Tissue Microarray and Automated Quantitative Analysis for Screening and Validation of Potential Biomarkers in Mantle Cell Lymphoma
    Yang DT, Quann PJ, Petrich AM, Leith CP, Young KH, Kahl BS
    Appl Immunohistochem Mol Morphol 2011 Jan;19(1):62-9
  • Bendamustine Pharmacokinetic Profile and Exposure-Response Relationships in Patients With Indolent Non-Hodgkin's Lymphoma
    Owen JS, Melhem M, Passarell JA, D'Andrea D, Darwish M, Kahl B
    Cancer Chemother Pharmacol 2010 Nov;66(6):1039-49
  • Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma: Results From a Multicenter Study
    Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD
    Cancer 2010 Jan 1;116(1):106-14
  • Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens
    Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW
    Clin Lymphoma Myeloma 2009 Aug;9(4):307-10
  • Comparison of Organ Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning--Patient Studies
    He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR, Flinn I, Hammes RJ, Bianco J, Kahl B, Frey EC
    Med Phys 2009 May;36(5):1595-601
  • Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma: Updated Time-To-Event Analyses of the Multicenter Phase 2 PINNACLE Study
    Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Nasta S, O'Connor OA, Shi H, Boral AL, Fisher RI
    Ann Oncol 2009 Mar;20(3):520-5
  • Phase II Study of Arsenic Trioxide and Ascorbic Acid for Relapsed or Refractory Lymphoid Malignancies: A Wisconsin Oncology Network Study
    Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS
    Hematol Oncol 2009 Mar;27(1):11-6
  • Augmented and Standard Berlin-Frankfurt-Munster Chemotherapy for Treatment of Adult Acute Lymphoblastic Leukemia
    Chang JE, Medlin SC, Kahl BS, Longo WL, Williams EC, Lionberger J, Kim K, Kim J, Esterberg E, Juckett MB
    Leuk Lymphoma 2008 Dec;49(12):2298-307
  • Bortezomib-Resistant Nuclear Factor-KappaB Activity in Multiple Myeloma Cells
    Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S
    Mol Cancer Res 2008 Aug;6(8):1356-64
  • Acute Promyelocytic Leukaemia and Acquired Alpha-2-Plasmin Inhibitor Deficiency: A Retrospective Look at the Use of Epsilon-Aminocaproic Acid (Amicar) in 30 Patients
    Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E
    Hematol Oncol 2008 Dec;26(4):241-6
  • Structural Profiles of TP53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study
    Young KH, Leroy K, Moller MB, Colleoni GW, Sanchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC
    Blood 2008 Oct 15;112(8):3088-98
  • Thalidomide Maintenance Following High-Dose Melphalan With Autologous Stem Cell Support in Myeloma
    Chang JE, Juckett MB, Callander NS, Kahl BS, Gangnon RE, Mitchell TL, Longo WL
    Clin Lymphoma Myeloma 2008 Jun;8(3):153-8
  • Prevalence of Bortezomib-Resistant Constitutive NF-KappaB Activity in Mantle Cell Lymphoma
    Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S
    Mol Cancer 2008 May 19;7:40
  • Phase II Study of Doxercalciferol for the Treatment of Myelodysplastic Syndrome
    Petrich A, Kahl B, Bailey H, Kim K, Turman N, Juckett M
    Leuk Lymphoma 2008 Jan;49(1):57-61
  • Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA
    J Clin Oncol 2007 May 1;25(13):1741-6
  • A 5-Drug Regimen Maximizing the Dose of Cyclophosphamide Is Effective Therapy for Adult Burkitt or Burkitt-Like Lymphomas
    Kujawski LA, Longo WL, Williams EC, Turman NJ, Brandt N, Mosher DF, Eickhoff JC, Kahl BS
    Cancer Invest 2007 Mar;25(2):87-93
  • A Pilot Study of Epratuzumab and Rituximab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy in Patients With Previously Untreated, Diffuse Large B-Cell Lymphoma
    Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM
    Cancer 2006 Dec 15;107(12):2826-32
  • Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A
    J Clin Oncol 2006 Oct 20;24(30):4867-74
  • Maintenance Rituximab Following Induction Chemoimmunotherapy May Prolong Progression-Free Survival in Mantle Cell Lymphoma: A Pilot Study From the Wisconsin Oncology Network
    Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, Rezazedeh H, Werndli J, Bailey HH
    Ann Oncol 2006 Sep;17(9):1418-23
  • Excessive Toxicity of the High Dose Thiotepa and Etoposide Regimen When Combined With Radiation: Long-Term Autologous Transplantation Experience in Follicular and Mantle Cell Lymphoma
    Fenske TS, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, McCoy AG, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL
    Leuk Lymphoma 2005 Oct;46(10):1441-8
  • Early Results of a Phase I Trial of Oblimersen Sodium for Relapsed or Refractory Waldenstrom's Macroglobulinemia
    Gertz MA, Geyer SM, Badros A, Kahl BS, Erlichman C
    Clin Lymphoma 2005 Mar;5(4):282-4
  • Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study
    Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, Williams EC, Longo WL, Kim KM, McGovern J, Jumonville A
    Cancer Invest 2005;23(1):13-8
  • A Novel Preparative Regimen for Autologous Transplant in Non-Hodgkin's Lymphoma: Long-Term Experience With Etoposide and Thiotepa
    McCoy AG, Smith EP, Atkinson ME, Baranski B, Kahl BS, Juckett M, Mitchell T, Gangnon R, Longo WL
    Bone Marrow Transplant 2004 Jan;33(1):19-24
  • Profound Imbalance of Pro-Fibrinolytic and Anti-Fibrinolytic Factors (Tissue Plasminogen Activator and Plasminogen Activator Inhibitor Type 1) and Severe Bleeding Diathesis in a Patient With Cirrhosis: Correction by Liver Transplantation
    Kahl BS, Schwartz BS, Mosher DF
    Blood Coagul Fibrinolysis 2003 Dec;14(8):741-4
  • Infectious Mononucleosis Progressing to Fatal Malignant Lymphoma: A Case Report and Review of the Literature
    Kobbervig C, Norback D, Kahl B
    Leuk Lymphoma 2003 Jul;44(7):1215-21
  • Hantavirus Pulmonary Syndrome in Wisconsin
    Kahl BS, Kumar A, Hale SJ, Hart MN, Badr S
    Wis Med J 1997 Feb;96(2):33-6

Invited Publications

Book Chapters

  • Non-Hodgkin Lymphoma
    Kahl BS, Mehta-Shah N
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • Treating Advanced Stage Follicular Lymphoma
    Cohen J, Kahl BS
    Follicular Lymphoma, Current Management on Novel Approaches. Springer Publishing 2018
  • Follicular Lymphoma: Are We Ready for a Risk-Adapted Approach?
    Kahl BS
    Hematology Am Soc Hematol Educ Program 2017 Dec 8;2017(1):358-364
  • Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies
    Cohen JB, Zain JM, Kahl BS
    Am Soc Clin Oncol Educ Book 2017;37:512-525
  • Non-Hodgkin’s Lymphoma
    Kahl BS, Yang D, Nowakowksi G
    American Society of Hematology Self-Assessment Program Book, 6th edition, Chapter 21, 2015
  • Non-Hodgkin’s Lymphoma
    Savage KS, Kahl BS
    American Society of Hematology Self-Assessment Program Book, 5th edition, Chapter 21, 2013
  • Is There a Role for "Watch and Wait" in Follicular Lymphoma in the Rituximab Era?
    Kahl B
    Hematology Am Soc Hematol Educ Program 2012;2012:433-8
  • Marginal Zone Lymphomas: Management of Nodal, Splenic, and MALT NHL
    Kahl B, Yang D
    Hematology Am Soc Hematol Educ Program 2008:359-64
  • Special Problems in B-Cell Lymphoma: An Historical Perspective
    Kahl BS
    Hematology Am Soc Hematol Educ Program 2008:340
  • New Therapeutic Strategies for Mantle Cell Lymphoma
    Kahl B
    American Society of Clinical Oncology Educational Book, 2008
  • Radiotherapy for Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Using Intensity Modulated Radiation Therapy Via Helical Tomotherapy: A New Mantle
    Welsh JS, Peterson C, Kahl B, Olivera G
    In: Intensity Modulated Radiation Therapy: A Clinical Perspective (Mundt AJ, Roeske JC, Eds.), BC Decker Inc. Publishers, Ch 24.2:553-555, 2005